Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

A pilot study of nadolol for overt aggression in developmentally delayed individuals.

Connor DF, Ozbayrak KR, Benjamin S, Ma Y, Fletcher KE.

J Am Acad Child Adolesc Psychiatry. 1997 Jun;36(6):826-34.

PMID:
9183139
2.

Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study.

Ratey JJ, Sorgi P, O'Driscoll GA, Sands S, Daehler ML, Fletcher JR, Kadish W, Spruiell G, Polakoff S, Lindem KJ, et al.

J Clin Psychiatry. 1992 Feb;53(2):41-6.

PMID:
1347291
3.

Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients.

Allan ER, Alpert M, Sison CE, Citrome L, Laury G, Berman I.

J Clin Psychiatry. 1996 Oct;57(10):455-9.

PMID:
8909331
4.
5.

Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.

McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, Cohen DJ.

J Am Acad Child Adolesc Psychiatry. 1997 May;36(5):685-93.

PMID:
9136504
6.

A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities.

Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT.

J Clin Psychiatry. 2001 Apr;62(4):239-48.

PMID:
11379837
7.

A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder.

Malone RP, Delaney MA, Luebbert JF, Cater J, Campbell M.

Arch Gen Psychiatry. 2000 Jul;57(7):649-54.

PMID:
10891035
8.

Impulsive aggressive behavior: open-label treatment with citalopram.

Reist C, Nakamura K, Sagart E, Sokolski KN, Fujimoto KA.

J Clin Psychiatry. 2003 Jan;64(1):81-5.

PMID:
12590628
10.

Effects of intravenous secretin on language and behavior of children with autism and gastrointestinal symptoms: a single-blinded, open-label pilot study.

Lightdale JR, Hayer C, Duer A, Lind-White C, Jenkins S, Siegel B, Elliott GR, Heyman MB.

Pediatrics. 2001 Nov;108(5):E90.

PMID:
11694674
11.

Effectiveness of lithium in children and adolescents with conduct disorder: a retrospective naturalistic study.

Masi G, Milone A, Manfredi A, Pari C, Paziente A, Millepiedi S.

CNS Drugs. 2009;23(1):59-69. doi: 10.2165/0023210-200923010-00004.

PMID:
19062775
12.

Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients' well-being.

Flevari P, Livanis EG, Theodorakis GN, Zarvalis E, Mesiskli T, Kremastinos DT.

J Am Coll Cardiol. 2002 Aug 7;40(3):499-504.

13.

Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study.

Peskind ER, Tsuang DW, Bonner LT, Pascualy M, Riekse RG, Snowden MB, Thomas R, Raskind MA.

Alzheimer Dis Assoc Disord. 2005 Jan-Mar;19(1):23-8.

PMID:
15764868
14.

Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, open-label study.

Cubo E, Fernández Jaén A, Moreno C, Anaya B, González M, Kompoliti K.

Clin Ther. 2008 Jan;30(1):182-9. doi: 10.1016/j.clinthera.2008.01.010.

PMID:
18343255
15.

Open-label use of placebos in the treatment of ADHD: a pilot study.

Sandler AD, Bodfish JW.

Child Care Health Dev. 2008 Jan;34(1):104-10. doi: 10.1111/j.1365-2214.2007.00797.x.

PMID:
18171451
16.

Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study.

Bellino S, Paradiso E, Bogetto F.

J Clin Psychiatry. 2006 Jul;67(7):1042-6.

PMID:
16889446
17.

Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years.

Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, Michele TM, Reiss TF, Nguyen HH, Bratton DL.

Pediatrics. 2001 Sep;108(3):E48.

PMID:
11533366
18.
19.

Physical aggression during admission to a child and adolescent inpatient unit: predictors and impact on clinical outcomes.

Dean AJ, Duke SG, Scott J, Bor W, George M, McDermott BM.

Aust N Z J Psychiatry. 2008 Jun;42(6):536-43. doi: 10.1080/00048670802050587.

PMID:
18465381
20.

Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy.

Shinnar S, Pellock JM, Conry JA.

Eur J Paediatr Neurol. 2009 Jan;13(1):3-9. doi: 10.1016/j.ejpn.2008.01.004. Epub 2008 Mar 14.

PMID:
18343174

Supplemental Content

Support Center